Omecu Ltd promises wide-ranging benefits in drug discovery and personalised medicine, while improving patient data security. A spin out from the University of Edinburgh, the company was formed in early 2021 to commercialise the research and development work from the university in this area.
About the team
Omecu Ltd is co-founded and draws on three years of research by Dr Canela-Xandri and Dr Rawlik alongside CEO Les Gaw, an experienced entrepreneur, investor and adviser to early-stage technology companies, who was introduced to the research team by Edinburgh Innovations.
Dr Konrad Rawlik
Chief Research Officer
Konrad is based at the Roslin Institute at the University of Edinburgh. He has extensive experience in the analysis of genetic data and is a specialist in machine learning. He has been working with Oriol for the last 8 years.
Our research partners are highly-accredited and established intitutions.
The University of Edinburgh
Dr Canela-Xandri and Rawlik have been supported by Edinburgh Innovations since 2019. Omecu received funding from the University’s Data-Driven Entrepreneurship Seed Fund and Fast Track Mentor initiatives, supported by the Scottish Funding Council.
Medical Research Council
MRC funds research at the forefront of science to prevent illness, develop therapies and improve human health. Omecu received funding support from Medical Research Council grants.
Omecu was awarded £288,000 from Innovate UK, enabling us to refine the prototype and progress commercial engagement.